NCT06216444

A Study of Remimazolam Tosilate for Sedation in Non-intubated Diagnostic and Therapeutic Procedures

A Multi-center, Randomized, Double-blind Clinical Study to Evaluate the Efficacy and Safety of Remimazolam Tosilate (Ruibeining®) for Injection for Sedation in Non-intubated Diagnostic and Therapeutic Procedures

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 240 (estimated)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of Remimazolam Tosilate for Injection for sedation in non-intubated diagnostic and therapeutic procedures

Conditions

• Sedation in Non-intubated Diagnostic and Therapeutic Procedures

Interventions

Type	Name	Description
DRUG	Remimazolam Tosilate for Injection	Initial loading dose of 5mg, with additional doses of 2.5mg as necessary
DRUG	Remimazolam Tosilate for Injection	Initial loading dose of 10mg, with additional doses of 2.5mg as necessary

Timeline

• Start date: 2024-01-01
• Primary completion: 2024-03-01
• Completion: 2024-03-01
• First posted: 2024-01-22
• Last updated: 2024-01-22

Locations

1 site across 1 country: China